[go: up one dir, main page]

Yin et al., 2024 - Google Patents

Oxytocin attenuates sympathetic innervation with inhibition of cardiac mast cell degranulation in rats after myocardial infarction

Yin et al., 2024

View HTML
Document ID
9111915603464682497
Author
Yin J
Wang Y
Han W
Ge W
Yu Q
Jing Y
Yan W
Liu Q
Gong L
Yan S
Wang S
Li X
Li Y
Hu H
Publication year
Publication venue
The Journal of Pharmacology and Experimental Therapeutics

External Links

Snippet

Sympathetic hyperinnervation is the leading cause of fatal ventricular arrhythmia (VA) after myocardial infarction (MI). Cardiac mast cells cause arrhythmias directly through degranulation. However, the role and mechanism of mast cell degranulation in sympathetic …
Continue reading at www.sciencedirect.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Similar Documents

Publication Publication Date Title
Jiang et al. cGAS knockdown promotes microglial M2 polarization to alleviate neuroinflammation by inhibiting cGAS-STING signaling pathway in cerebral ischemic stroke
De Jesus et al. Antiarrhythmic effects of interleukin 1 inhibition after myocardial infarction
Li et al. MicroRNA-328 as a regulator of cardiac hypertrophy
Moccia et al. Endothelial remodelling and intracellular calcium machinery
Mosqueira et al. Cardiac and respiratory dysfunction in Duchenne muscular dystrophy and the role of second messengers
Peng et al. L-3-n-butylphthalide reduces tau phosphorylation and improves cognitive deficits in AβPP/PS1-Alzheimer's transgenic mice
Egom et al. Impaired sinoatrial node function and increased susceptibility to atrial fibrillation in mice lacking natriuretic peptide receptor C
US8193151B2 (en) Methods for treating atrial or ventricular arrhythmias
US12433932B2 (en) Ang (1-7) derivative oligopeptides for the treatment of pain
US20140205577A1 (en) Treatment of Cardiovascular Disorders Using the Cell Differentiation Signaling Protein Nell1
Yin et al. Oxytocin attenuates sympathetic innervation with inhibition of cardiac mast cell degranulation in rats after myocardial infarction
CN108853505A (en) Use and pharmaceutical composition of potassium ion channel inhibitor for treating depression
CN110041408A (en) A kind of micromolecule polypeptide and its application in preparation prevention and treatment parkinsonism drug
CN109715190A (en) Pharmaceutical associations of growth factor receptor agonists and adhesion protein inhibitors for converting neoplastic cells to non-neoplastic cells and uses thereof
WO2025030135A2 (en) Methods for treating and ameliorating angina, myocardial infarction, reperfusion injury, heart arrhythmias and congestive heart failure (chf)
Ohsawa et al. Caveolin-3 regulates myostatin signaling. Mini-review
Hu et al. Oxytocin attenuates sympathetic innervation with inhibition of cardiac mast cell degranulation in rats post myocardial infarction
Chen et al. Eplerenone inhibits atrial fibrosis in mutant TGF-β1 transgenic mice
KR102213878B1 (en) Composition for prevention, improving or treatment of chronic pain comprising PAT4
CN108047315B (en) Polypeptide drug Athycaltide and application thereof
US8518884B2 (en) Methods for treating atrial or ventricular arrhythmias by administering a G-protein alpha inhibitor
Zhan et al. Decreased expression of adenosine receptor 2B confers cardiac protection against ischemia via restoring autophagic flux
Zhou et al. Hyperpolarization-activated cyclic nucleotide-gated channel gene: The most possible therapeutic applications in the field of cardiac biological pacemakers
Akerman Calcium signalling in atrial myocytes and potential targets for atrial fibrillation
Dorey Phosphodiesterases mediate neurohumoral regulation of sinoatrial node and atrial arrhythmogenesis